Completed PHASE2 INTERVENTIONAL 2-arm NCT01189812

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders

Sponsor: Columbia Northwest Pharmaceuticals

Conditions Borderline Personality Disorder Depression Not Otherwise Specified Dysthymia Major Depressive Disorder

Interventions Citalopram Lithium Carbonate Placebo

Updated 6 times since 2017 Last updated: Aug 22, 2011 Started: Mar 31, 2010 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Borderline Personality Disorder and Depression Not Otherwise Specified and is currently completed. Columbia Northwest Pharmaceuticals leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Columbia Northwest Pharmaceuticals

Data source: Columbia Northwest Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bellevue, United States
• San Diego, United States